Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions.

Filppula AM, Mustonen TM, Backman JT.

Basic Clin Pharmacol Toxicol. 2018 Jun 28. doi: 10.1111/bcpt.13088. [Epub ahead of print]

PMID:
29956478
2.

Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans.

Itkonen MK, Tornio A, Filppula AM, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT.

Clin Pharmacol Ther. 2017 Nov 24. doi: 10.1002/cpt.947. [Epub ahead of print]

PMID:
29171020
3.

Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions.

Kahma H, Filppula AM, Neuvonen M, Tarkiainen EK, Tornio A, Holmberg MT, Itkonen MK, Finel M, Neuvonen PJ, Niemi M, Backman JT.

Drug Metab Dispos. 2018 Feb;46(2):141-150. doi: 10.1124/dmd.117.078162. Epub 2017 Nov 14.

PMID:
29138287
4.

Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.

Backman JT, Filppula AM, Niemi M, Neuvonen PJ.

Pharmacol Rev. 2016 Jan;68(1):168-241. doi: 10.1124/pr.115.011411. Review.

5.

Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma.

Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K.

Br J Clin Pharmacol. 2016 Feb;81(2):313-5.

6.

Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions.

Tornio A, Filppula AM, Kailari O, Neuvonen M, Nyrönen TH, Tapaninen T, Neuvonen PJ, Niemi M, Backman JT.

Clin Pharmacol Ther. 2014 Oct;96(4):498-507. doi: 10.1038/clpt.2014.141. Epub 2014 Jun 27.

PMID:
24971633
7.

In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors.

Filppula AM, Neuvonen PJ, Backman JT.

Drug Metab Dispos. 2014 Jul;42(7):1202-9. doi: 10.1124/dmd.114.057695. Epub 2014 Apr 8.

8.

Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.

Filppula AM, Tornio A, Niemi M, Neuvonen PJ, Backman JT.

Clin Pharmacol Ther. 2013 Sep;94(3):383-93. doi: 10.1038/clpt.2013.92. Epub 2013 May 8.

PMID:
23657159
9.

Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.

Filppula AM, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT.

Drug Metab Dispos. 2013 Jan;41(1):50-9. doi: 10.1124/dmd.112.048017. Epub 2012 Oct 1.

10.

Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.

Filppula AM, Laitila J, Neuvonen PJ, Backman JT.

Br J Pharmacol. 2012 Apr;165(8):2787-98. doi: 10.1111/j.1476-5381.2011.01732.x.

11.

Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations.

Filppula AM, Laitila J, Neuvonen PJ, Backman JT.

Drug Metab Dispos. 2011 May;39(5):904-11. doi: 10.1124/dmd.110.037689. Epub 2011 Feb 2.

Supplemental Content

Loading ...
Support Center